Avadel pharmaceuticals announces favorable ruling in appeal of delaware court injunction

- with this ruling, avadel can seek and be granted fda approval for lumryz in idiopathic hypersomnia - - federal circuit decision permits new clinical trials and further development of lumryz™  for the treatment of indications beyond narcolepsy - dublin, ireland, may 06, 2025 (globe newswire) -- avadel pharmaceuticals plc (nasdaq: avdl), a biopharmaceutical company focused on transforming medicines to transform lives, today announced that the united states court of appeals for the federal circuit (the “federal circuit”) has ruled in favor of avadel, overturning important parts of the injunction imposed by the u.s. district court for the district of delaware (the “delaware court”) regarding lumryz™ as a potential treatment of indications beyond narcolepsy. the federal circuit vacated the portion of the injunction that prohibited avadel from applying for fda approval of lumryz for any indication beyond narcolepsy, calling the district court's analysis “simply too speculative and tenuous.
AVDL Ratings Summary
AVDL Quant Ranking